SINGAPORE (Aug 23): Clearbridge Health’s wholly-owned subsidiary, SAM Laboratory, is acquiring a controlling stake in PT Indo Genesis Medika, a company incorporated in Indonesia, for an aggregate consideration of about IDR 40.7 billion ($3.8 million).

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply